A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
2006; Massachusetts Medical Society; Volume: 355; Issue: 22 Linguagem: Inglês
10.1056/nejmoa060326
ISSN1533-4406
AutoresRenata Belfort, Stephen A. Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin O. Tio, Joseph P. Pulcini, Rachele Berria, Z. Jennie, Sunil Kumar Dwivedi, Russell Havranek, Chris Fincke, Ralph A. DeFronzo, George A. Bannayan, Steven Schenker, Kenneth Cusi,
Tópico(s)Metabolism, Diabetes, and Cancer
ResumoNo pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus.
Referência(s)